Health iQ have been announced as double finalists at the upcoming annual Pharmaceutical Market Excellence Awards (PMEA) 2017.
The nominations are in the highly prized categories of ‘Excellence in Rare Diseases and Orphan Drugs’ and in ‘Excellence in Innovation’.Health iQ has been recognized for its work with Sanofi Genzyme for the entry, ‘Make The Connection’ – Helping Paediatricians Join the Dots to Recognise MPS I. This was the same innovative project that saw Sanofi Genzyme and Health iQ awarded an Inspiration Award at the recent PM Society Digital Awards 2017 – the most prestigious digital focused event in the calendar for companies and agencies working in the pharmaceutical industry.
These respected awards are run by the PMGroup, which also runs the Communiqúe Awards. The PMEA Awards aim to recognise excellence in improving patient outcomes and includes three new categories for 2017:
- Excellence in Engagement Through Multiple Channels (Digital and Traditional)
- Excellence in Creating Value Beyond the Product
- Excellence in Demonstrating Economic and Societal Value
The awards will take place this year on 15 November 2017 in London.
Notes to editors
Health iQ is a privately-owned company based in London specializing in insight into real world healthcare data, based on an outstanding heritage of working in the NHS. It now works with more than half of the top 100 global Life Science firms.
The PMGroup runs the PMLiVE website and its associated monthly print magazine Pharmaceutical Market Europe (PME). Two twice-yearly print titles, Communiqué and The Directory, are also published by the group alongside organizing two annual Awards; the Pharmaceutical Market Excellence Awards (PMEAs) and the Communiqué Awards.
PMEA 2017 will be presented at a black tie dinner on Wednesday 15 November 2017 at Sheraton Grand Park Lane. More information on the finalists is available at http://www.pmlive.com/awards/pmea/finalists_2017